Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)’s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.30 and traded as low as $3.24. Galmed Pharmaceuticals shares last traded at $3.37, with a volume of 24,216 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a research report on Wednesday, October 9th. They set a “sell” rating on the stock.

Galmed Pharmaceuticals Stock Up 4.0 %

The stock has a market capitalization of $2.17 million, a price-to-earnings ratio of -0.20 and a beta of 0.80. The company’s 50-day simple moving average is $4.75 and its 200 day simple moving average is $4.30.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share (EPS) for the quarter.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.